The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: a meta-analysis.
Published data on the association between E-cadherin (CDH1) -160 C/A polymorphism and prostate cancer (PCA) risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. A logistic regression approach proposed for molecular association studies was used to estimate a biological model of the gene effect. A total of 11 studies including 2637 cases and 2673 controls were involved in this meta-analysis. Logistic regression analysis indicated that the CDH1 -160 C/A genotypes were associated with PCA risk. The genetic model test indicated that the genetic model was most likely to be dominant (CA+AA vs CC). Overall, meta-analysis indicated that the -160A allele carriers (CA+AA) had a 21% elevated risk of PCA, when compared with the homozygotes (CC) (odds ratio (OR)=1.21; 95% confidence interval (CI): 0.97-1.51; P=0.090, P(heterogeneity)=0.001). In the subgroup analyses by ethnicity, significantly elevated risks were associated with -160 variant genotypes (CA+AA) in both European and Asian populations (OR=1.24; 95% CI: 1.08-1.43; P=0.003, P(heterogeneity)=0.220 and OR=1.54; 95% CI: 1.23-1.93; P<0.001, P(heterogeneity)=0.200). However, no significant associations were found in Africans (OR=0.59; 95% CI: 0.32-1.09; P=0.090, P(heterogeneity)=0.070). Although some modest bias could not be eliminated, this meta-analysis suggests that the CDH1 -160A allele is a low-penetrant risk factor for developing PCA, especially in Europeans and Asians.
Qiu
Li-Xin
LX
Cancer Center, Nanjing Drum Tower Hospital, Nanjing Medical University, Nanjing, China.
Li
Ru-Tian
RT
Zhang
Jian-Bing
JB
Zhong
Wen-Zhao
WZ
Bai
Jian-Ling
JL
Liu
Bao-Rui
BR
Zheng
Ming-Hua
MH
Qian
Xiao-Ping
XP
D015820:Cadherins / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D016015:Logistic Models; D008297:Male; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics*
D015820:Cadherins
Jpn J Clin Oncol. 2005 Mar;35(3):158-61
15741307
Cancer Cell Int. 2003 Oct 14;3(1):17
14613514
Genet Med. 2002 Mar-Apr;4(2):45-61
11882781
Int J Cancer. 2004 Apr 10;109(3):348-52
14961571
Int J Cancer. 2002 Aug 20;100(6):683-5
12209606
N Engl J Med. 2000 Jul 13;343(2):78-85
10891514
Hum Genet. 2005 Dec;118(3-4):339-47
16189707
Science. 1991 Mar 22;251(5000):1451-5
2006419
J R Soc Promot Health. 2004 Sep;124(5):219-21
15493781
J Urol. 2006 Aug;176(2):793-6
16813949
Cancer. 2002 Mar 1;94(5):1443-8
11920500
Cancer Res. 1994 Jul 15;54(14):3929-33
7518346
Ann Hum Genet. 1955 Jun;19(4):251-3
14388528
Trends Genet. 2004 Sep;20(9):439-44
15313553
Hum Mutat. 1998;12(4):226-37
9744472
Mutat Res. 2002 May 22;502(1-2):19-24
11996968
J Natl Cancer Inst. 2004 Mar 17;96(6):434-42
15026468
Cancer Lett. 2003 May 30;195(1):53-8
12767511
Stat Med. 2005 May 15;24(9):1291-306
15568190
Cancer Res. 2000 Feb 15;60(4):873-6
10706097
Endocr Relat Cancer. 2003 Jun;10(2):225-59
12790786
Urol Int. 2004;72(3):203-7
15084762
World J Urol. 2004 Feb;21(6):414-23
14648103
Int J Cancer. 2004 Apr 10;109(3):480-1
14961592
Urology. 2007 Jul;70(1):127-30
17656222
BJU Int. 2000 Nov;86(7):869-78
11069416
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Prostate. 2006 Apr 1;66(5):546-56
16372334
Epidemiology. 1997 Nov;8(6):653-7
9345665